Medical Writing & Pharma

Why Subject Matter Experts Are Essential in Creating AI-Enabled Medical Writing Tools

By pwsadmin / December 6, 2024 /

AgileWriter™ is an AI tool designed specifically for medical writing, developed by experts in the field to meet the precise needs of clinical documentation. Importance of Subject Matter Experts: Involving subject matter experts (SMEs) in the creation of AI tools for medical writing ensures the tool is practical and meets user needs, avoiding misalignment and inefficiencies. Consequences of Excluding SMEs: Without direct input from medical writers, AI tools may focus on flashy features rather than essential functions, leading to misaligned priorities, extra user steps, and lost productivity. Benefits of AgileWriter™ are developed by medical writing leaders, integrates seamlessly into workflows, reducing guesswork and enhancing writing efficiency.

Read More

The Critical Role of Medical Writers in Pediatric Drug Development

By Alex Olinger / November 14, 2024 / Comments Off on The Critical Role of Medical Writers in Pediatric Drug Development

Pediatric drug development is one of the most challenging areas of regulatory writing, where precision, guidance interpretation, and strategic planning are crucial to achieving regulatory success. Medical writers play a pivotal role in ensuring that regulatory submissions are clear, compliant, and robust enough to meet the unique needs of pediatric populations. In this blog, we’ll…

Read More

Navigating Medication Jenga: The Challenge of Polypharmacy in Geriatric Patients

By Alex Olinger / November 11, 2024 / Comments Off on Navigating Medication Jenga: The Challenge of Polypharmacy in Geriatric Patients

As we age, the complexity of our health often increases, leading to the management of multiple chronic conditions. This reality gives rise to a phenomenon known as polypharmacy, or the simultaneous use of multiple medications in a single patient. Polypharmacy is a significant concern, particularly among geriatric patients, where it is sometimes referred to more…

Read More

Insulin: The Savior of Millions

By Alex Olinger / November 8, 2024 / Comments Off on Insulin: The Savior of Millions

According to the National Diabetes Statistics Report,1 5.7% of all United States (US) adults with type 1 diabetes rely on insulin for managing their condition. Additionally, approximately 12.3% of US adults starting using insulin within a year of their diabetes diagnosis. Insulin stands as a cornerstone in the treatment regimen, offering hope and vitality to…

Read More

Bug Busters: Creative Combat Against Drug-Resistant Infections

By Alex Olinger / November 5, 2024 / Comments Off on Bug Busters: Creative Combat Against Drug-Resistant Infections

In the ever-evolving battle against infectious diseases, the rise of drug-resistant infections poses a significant challenge to global health. These resilient bugs have developed mechanisms to withstand conventional treatments, leaving scientists and healthcare professionals searching for innovative solutions. In this blog post, we will explore the world of bug busters—the creative strategies, and the minds…

Read More

Navigating the Frontier: An Introduction to Investigational New Drug (IND)

By Alex Olinger / October 9, 2024 / Comments Off on Navigating the Frontier: An Introduction to Investigational New Drug (IND)

In the realm of pharmaceutical innovation, the Investigational New Drug (IND) application is a pivotal gateway, marking the initiation of clinical trials and the potential journey toward a groundbreaking new medication. Let’s explore the significance and process of an IND and its role in bringing novel therapies from the lab bench to the patient’s bedside.…

Read More

Harvest of Sorrow: The CKDu Crisis

By Alex Olinger / October 3, 2024 / Comments Off on Harvest of Sorrow: The CKDu Crisis

Chronic Kidney Disease of Unknown Etiology (CKDu) has emerged as a pressing public health concern, particularly in regions with high agricultural activity and limited access to healthcare. Afflicting predominantly rural communities in low- and middle-income countries, CKDu poses a significant challenge due to its elusive causes, devastating health consequences, and socioeconomic impact. The phenomenon of…

Read More

Key Considerations for Submitting Your NDA or BLA to FDA on a Rolling Basis

By Alex Olinger / September 6, 2024 / Comments Off on Key Considerations for Submitting Your NDA or BLA to FDA on a Rolling Basis

Establishing early alignment with the FDA on the rolling submission approach is pivotal to your success. Before you initiate any submission activities, ensure you have secured the FDA’s agreement on both the timing and the scope of your rolling submission. This early communication ensures that there are no surprises later and allows both you and…

Read More

Biosimilar Laughs: A Chuckle in Every Dose

By Alex Olinger / August 28, 2024 / Comments Off on Biosimilar Laughs: A Chuckle in Every Dose

What is a Biosimilar? In the scientific realm, biosimilars, akin to their reference products, are biologic medications. Approval for biosimilars hinges on demonstrating no clinically significant differences in safety and efficacy compared to the reference products. Picture them as biological siblings, crafted from the same sources as live cells or microbes, ensuring the same safety…

Read More

10 Most Common Risks to Your BLA or NDA Timeline (and How to Mitigate Them)

By Alex Olinger / August 25, 2024 / Comments Off on 10 Most Common Risks to Your BLA or NDA Timeline (and How to Mitigate Them)

When pursuing a Biologics License Application (BLA) or New Drug Application (NDA), meeting timelines is crucial. However, the path to approval is often fraught with potential delays. Understanding these risks—and knowing how to mitigate them—can make or break your timeline. Top 10 most common risks and expert tips on how to manage them effectively 1.…

Read More